Results 121 to 130 of about 13,224,808 (358)
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
Molecular Oncology, EarlyView.WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet +17 morewiley +1 more sourceExploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells
Molecular Oncology, EarlyView.We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair +17 morewiley +1 more sourceSharing and community curation of mass spectrometry data with Global Natural Products Social Molecular Networking
Nature Biotechnology, 2016 Mingxun Wang, Jeremy J. Carver, Vanessa V. Phelan, Laura M. Sanchez, Neha Garg, Yao Peng, Don D. Nguyen, J. Watrous, Clifford A. Kapono, Tal Luzzatto-Knaan, Carla Porto, Amina Bouslimani, A. Melnik, Michael J. Meehan, Wei-Ting Liu, M. Crüsemann, Paul D. Boudreau, E. Esquenazi, Mario Sandoval-Calderón, R. Kersten, L. Pace, R. Quinn, Katherine R. Duncan, Cheng-Chih Hsu, D. Floros, R. Gavilán, Karin Kleigrewe, T. Northen, R. Dutton, D. Parrot, Erin E. Carlson, B. Aigle, C. F. Michelsen, L. Jelsbak, Christian Sohlenkamp, P. Pevzner, A. Edlund, J. McLean, J. Piel, B. Murphy, L. Gerwick, C. Liaw, Yu-Liang Yang, H. Humpf, M. Maansson, R. Keyzers, A. Sims, Andrew R. Johnson, A. Sidebottom, Brian E. Sedio, Andreas K. Klitgaard, Charles B. Larson, Cristopher A Boya P, Daniel Torres-Mendoza, D. Gonzalez, D. Silva, L. M. Marques, D. Demarque, E. Pociūtė, E. O’Neill, Enora Briand, Eric J. N. Helfrich, Eve A Granatosky, E. Glukhov, Florian Ryffel, H. Houson, H. Mohimani, Jenan J. Kharbush, Yi Zeng, J. Vorholt, Kenji L. Kurita, Pep Charusanti, K. McPhail, K. Nielsen, L. Vuong, Maryam Elfeki, Matthew F. Traxler, Niclas Engene, Nobuhiro Koyama, Oliver B. Vining, R. Baric, Ricardo R. Silva, Samantha J. Mascuch, S. Tomasi, Stefan Jenkins, V. Macherla, Thomas Hoffman, V. Agarwal, P. Williams, Jingqui Dai, R. Neupane, Joshua R. Gurr, A. M. C. Rodriguez, Anne Lamsa, Chen Zhang, Kathleen Dorrestein, B. Duggan, J. Almaliti, Pierre-Marie Allard, P. Phapale, Louis-Félix Nothias, T. Alexandrov, M. Litaudon, J. Wolfender, J. Kyle, T. Metz, Tyler Peryea, Dac-Trung Nguyen, Danielle Vanleer, P. Shinn, A. Jadhav, R. Müller, K. Waters, Wenyuan Shi, Xueting Liu, Lixin Zhang, R. Knight, P. Jensen, B. Palsson, K. Pogliano, Roger G. Linington, Marcelino Gutiérrez, N. Lopes, W. Gerwick, B. Moore, P. Dorrestein, N. Bandeira +126 moresemanticscholar +1 more sourceLINC01116, a hypoxia‐lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma
Molecular Oncology, EarlyView.The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...Marine Gautier‐Isola, Rafael Lopes Goncalves, Marin Truchi, Caroline Lacoux, Célia Scribe, Hugo Cadis, Laetitia Guardini, Sophie Bekisz, Marius Ilié, Paul Hofman, Georges Vassaux, Bernard Mari, Roger Rezzonico +12 morewiley +1 more sourceDeveloping evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities
Molecular Oncology, EarlyView.The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking +43 morewiley +1 more source
